Associations of ctDNA levels during neoadjuvant treatment with pathological response in patients with resectable NSCLC from the phase 3 AEGEAN trial

被引：2
|
作者：
Gale, Davina
Zhu, Zhou
Lai, Zhongwu
Reck, Martin
Harpole, David
Taube, Janis M.
Mitsudomi, Tetsuya
Hochmair, Maximilian
Winder, Thomas
Urban, Laszlo
Rodriguez-Cid, Jeronimo
Chu, Quincy
Chaft, Jamie
Stewart, Ross
Hodgson, Darren
Doherty, Gary J.
Heymach, John V.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT238
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT238
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Associations of ctDNA clearance and pathological response with neoadjuvant treatment in patients with resectable NSCLC from the phase III AEGEAN trial
    Reck, M.
    Gale, D.
    Harpole, D.
    Taube, J. M.
    Mitsudomi, T.
    Hochmair, M. J.
    Winder, T.
    Zhu, Z.
    Lai, Z.
    Stewart, R.
    Hodgson, D. R.
    Doherty, G. J.
    Heymach, J. V.
    ANNALS OF ONCOLOGY, 2023, 34 : S1300 - S1300
  • [2] ctDNA dynamics and neoadjuvant treatment responses in patients with resectable NSCLC from the phase 3 AEGEAN trial
    Schumann, Christian
    Heymach, John V.
    Harpole, David
    Mitsudomi, Testuya
    Taube, Janis M.
    Galffy, Gabriella
    Hochmair, Maximilian
    Winder, Thomas
    Zukov, Ruslan
    Garbaos, Gabriel
    Gao, Shugeng
    Kuroda, Hiroaki
    You, Jian
    Lee, Kang-Yun
    Antonuzzo, Lorenzo
    Aperghis, Mike
    Doherty, Gary J.
    Mann, Helen
    Fouad, Tamer M.
    Reck, Martin
    Becker, Silvan
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 126 - 127
  • [3] Associations of ctDNA clearance (CL) during neoadjuvant Tx with pathological response and event-free survival (EFS) in pts with resectable NSCLC (R-NSCLC): Expanded analyses from AEGEAN
    Reck, M.
    Gale, D.
    Zhu, Z.
    Harpole, D.
    Taube, J.
    Mitsudomi, T.
    Van Luong, D.
    Hochmair, M. J.
    Lee, K-Y.
    Horio, Y.
    Urban, L.
    Akamatsu, H.
    Biswas, B.
    Antonuzzo, L.
    Szalai, Z.
    Stewart, R.
    Lai, Z.
    Hodgson, D.
    Doherty, G.
    Heymach, J. V.
    ANNALS OF ONCOLOGY, 2024, 35 : 1239 - 1239
  • [4] The AEGEAN Phase 3 Trial of Neoadjuvant/Adjuvant Durvalumab in Patients with Resectable Stage II/III NSCLC
    Heymach, J.
    Taube, J.
    Mitsudomi, T.
    Harpole, D.
    Aperghis, M.
    Trani, L.
    Powell, M.
    Dennis, P.
    Reck, M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S625 - S626
  • [5] AEGEAN: a phase 3 trial of neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC
    Schumann, C.
    Heymach, J. V.
    Harpole, D.
    Mitsudomi, T.
    Taube, J. M.
    Galffy, G.
    Hochmair, M.
    Winder, T.
    Zukov, R.
    Garbaos, G.
    Gao, S.
    Kuroda, H.
    You, J.
    Lee, K. -Y.
    Antonuzzo, L.
    Aperghis, M.
    Doherty, G. J.
    Mann, H.
    Fouad, T. M.
    Reck, M.
    Weissinger, F.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 8 - 9
  • [6] Associations of ctDNA clearance and pathological response after neoadjuvant treatment in patients with locally advanced oral cancer
    Zhong, Lai-ping
    Zhou, Zhi-hang
    Huang, Ying-ying
    Zhang, Yi-yi
    Lu, Yi
    Li, Bing
    Wang, Jing
    Zhao, Tong-chao
    Ju, Wu-tong
    Zhu, Dong-wang
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] TCR Repertoire Predicts Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemoimmunotherapy from NADIM Trial
    Casarrubios, M.
    Nadal, E.
    Cruz-Bermudez, A.
    Insa, A.
    Laza Briviesca, R.
    Garcia Campelo, M. R.
    Sierra-Rodero, B.
    Casal, J.
    Domine, M.
    Massuti, B.
    Majem Tarruella, M.
    Rodriguez-Abreu, D.
    Martinez-Marti, A.
    De Castro Campeno, J.
    Cobo Dols, M.
    Lopez Vivanco, G.
    Del Barco, E.
    Bernabe Caro, R.
    Vinolas, N.
    Barneto, I.
    Viteri, S.
    Jove, M.
    Franco, F.
    Provencio, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S545 - S546
  • [8] Nivolumab plus chemotherapy versus chemotherapy as neoadjuvant treatment for resectable stage IIIA NSCLC: Primary endpoint results of pathological complete response (pCR) from phase II NADIM II trial.
    Provencio-Pulla, Mariano
    Nadal, Ernest
    Larriba, Jose Luis Gonzalez
    Martinez-Marti, Alex
    Bernabe, Reyes
    Bosch-Barrera, Joaquim
    Casal, Joaquin
    Calvo, Virginia
    Insa, Amelia
    Aix, Santiago Ponce
    Reguart, Noemi
    Carpeno, Javier De Castro
    Mosquera, Joaquin
    Benitez, Raquel
    De La Rosa, Carlos Aguado
    Palmero, Ramon
    Hernando-Trancho, Florentino
    Romero, Atocha
    Bermudez, Alberto Cruz
    Massuti, Bartomeu
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] Neoadjuvant Atezolizumab in Resectable NSCLC Patients: Immunophenotyping Results from the Interim Analysis of the Multicenter Trial LCMC3
    Oezkan, F.
    He, K.
    Owen, D.
    Pietrzak, M.
    Cho, J. H.
    Kitzler, R.
    Pearson, R.
    Rusch, V.
    Chaft, J.
    Suh, R.
    Blasberg, J.
    Reckamp, K.
    Raz, D.
    Kneuertz, P.
    Fiorillo, L.
    Garon, E.
    Nicholas, A.
    Johnson, A.
    Schulze, K.
    Grindheim, J.
    Banchereau, R.
    Phan, S.
    Bunn, P., Jr.
    Kwiatkowski, D.
    Johnson, B.
    Kris, M.
    Wistuba, I.
    Lee, J.
    Lozanski, G.
    Carbone, D.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S242 - S243
  • [10] Peripheral blood markers associated with treatment response and survival in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
    Hu, Yan
    Ren, Siying
    Wu, Fang
    Liu, Wenliang
    RESPIROLOGY, 2023, 28 : 118 - 118
12345